Daclatasvir Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors.Daclatasvir Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Daclatasvir Nitroso CAS NO:NA chemically represented as Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1-nitroso-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate. Synchemia is the leading manufacturing and exporter of Daclatasvir Nitroso . We supply Daclatasvir Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143156 |
| CAS No | NA |
| Mol.F. | C24H23N7O3 |
| Mol.Wt. | 457.49 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143157 |
| CAS No | NA |
| Mol.F. | C29H27N7O6 |
| Mol.Wt. | 569.58 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143158 |
| CAS No | NA |
| Mol.F. | C30H31N7O7 |
| Mol.Wt. | 601.62 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143159 |
| CAS No | NA |
| Mol.F. | C13H21N3O4 |
| Mol.Wt. | 283.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143160 |
| CAS No | NA |
| Mol.F. | C12H21N3O4 |
| Mol.Wt. | 271.32 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143161 |
| CAS No | NA |
| Mol.F. | C17H18N4O5S |
| Mol.Wt. | 390.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143162 |
| CAS No | NA |
| Mol.F. | C16H16N4O4S |
| Mol.Wt. | 360.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143163 |
| CAS No | NA |
| Mol.F. | C16H16N4O3S |
| Mol.Wt. | 344.39 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143164 |
| CAS No | NA |
| Mol.F. | C16H15ClN4O2S |
| Mol.Wt. | 362.83 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143165 |
| CAS No | NA |
| Mol.F. | C16H16N4O3S |
| Mol.Wt. | 344.39 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143166 |
| CAS No | NA |
| Mol.F. | C15H14N4O2S |
| Mol.Wt. | 314.36 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143167 |
| CAS No | NA |
| Mol.F. | C8H7N3O2S |
| Mol.Wt. | 209.22 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143168 |
| CAS No | NA |
| Mol.F. | C16H16N4O3S |
| Mol.Wt. | 344.39 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143169 |
| CAS No | NA |
| Mol.F. | C17H18N4O3S |
| Mol.Wt. | 358.42 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143170 |
| CAS No | NA |
| Mol.F. | C17H18N4O5S |
| Mol.Wt. | 390.41 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143171 |
| CAS No | NA |
| Mol.F. | C16H15ClN4O3S |
| Mol.Wt. | 378.83 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |